Repros Theraup (NASDAQ:RPRX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Results 1 - 15 of 15

Recs

0
Member Avatar DeathStock (99.25) Submitted: 10/23/2015 12:46:04 PM : Outperform Start Price: $6.08 RPRX Score: -64.99

Accidentally green thumbed this when I meant underperform. I've got to slow down when entering these picks. Hopefully I can break-even.

Recs

0
Member Avatar snowgoon42 (94.67) Submitted: 4/5/2015 11:33:08 AM : Outperform Start Price: $8.76 RPRX Score: -74.40

Bulls and Bears Trapper John

Recs

2
Member Avatar liszewski (99.95) Submitted: 10/21/2011 11:20:37 PM : Underperform Start Price: $4.03 RPRX Score: +110.98

Zonagen. lol.

Recs

1
Member Avatar rodessa (51.91) Submitted: 7/26/2011 7:12:18 AM : Underperform Start Price: $6.52 RPRX Score: +119.82

This company should take the same way as CBLI in the coming weeks as nothing at all can justify it's actual market price.To short without any moderation!!!

Recs

0
Member Avatar bridgeboy0 (32.25) Submitted: 2/4/2011 12:27:17 PM : Underperform Start Price: $3.30 RPRX Score: +90.76

From goldminingXpert

Recs

0
Member Avatar goldminingXpert (29.70) Submitted: 2/3/2011 1:25:49 PM : Underperform Start Price: $2.53 RPRX Score: +71.04

Still broke, still no drug. The Zonagen saga continues...

Recs

1
Member Avatar ravens9111 (< 20) Submitted: 12/24/2010 12:45:17 AM : Outperform Start Price: $1.44 RPRX Score: -11.75

Might be late to the party but I think even if it pulls back there is still more upside here.

Recs

1
Member Avatar panochey (< 20) Submitted: 1/19/2009 8:42:52 AM : Outperform Start Price: $45.96 RPRX Score: -242.73

Repros Therapeutics Inc. Announces That Proellex Significantly Reduced Pain in a U.S. Phase 2 Clinical Trial (Jan 2009)
Anything that helps Momma with the monthlies is gonna sell well. Oh, and minimal debt.

Recs

0
Member Avatar smallcapinvest (85.54) Submitted: 12/17/2008 11:14:11 AM : Outperform Start Price: $42.52 RPRX Score: -226.62

little gamble since fundamentals are so bad, but MACD looks good, STO is converging and I am hoping for a crossover

Recs

0
Member Avatar SanDieguito (23.94) Submitted: 12/3/2007 3:08:08 PM : Underperform Start Price: $30.60 RPRX Score: +138.54

down $2 to $7

Recs

0
Member Avatar ProphetOfProfits (41.19) Submitted: 7/27/2007 10:59:02 AM : Outperform Start Price: $52.80 RPRX Score: -142.37

Good clinical data re Proellex safety is a good enough reason for me to hop in again

Recs

0
Member Avatar jbfoolsgold (< 20) Submitted: 7/17/2007 10:47:22 PM : Outperform Start Price: $52.64 RPRX Score: -135.76

Strong development pipeline, product potentials and buyout potentials. It is just a matter of time before something happens to push to $20.

Recs

0
Member Avatar Molucre (71.29) Submitted: 2/15/2007 6:27:13 PM : Outperform Start Price: $43.80 RPRX Score: -144.61

Blockbuster drug with excellent Phase II data. Company will be bought out before the end of Phase III.

Recs

2
Member Avatar foolphighter (< 20) Submitted: 1/12/2007 1:46:41 AM : Outperform Start Price: $48.96 RPRX Score: -148.63

Micro biotech recently announced statistically significant results for its lead drug Proellex in two different indications and non-inferiority in another drug, Androxal.

with only 10M shares o/s, and just under a $1/share in cash, a financing appears to be in the company's near term future, but given the recent run-up in price, the dilution should help increase liquidity & institutional ownership while making it fairly painless for current shareholders. good speculative bet over the next 12 to 24 months.

Recs

0
Member Avatar BongoBilly (< 20) Submitted: 12/27/2006 7:13:26 AM : Outperform Start Price: $47.40 RPRX Score: -148.74

Significantly undervalued south of $25

Results 1 - 15 of 15

Featured Broker Partners